12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga_article·Oct 13, 2026 at 05:06 PMAPLM+3.39%CDT-10.16%
Cadrenal Therapeutics launches formal strategic review, retains Tungsten Advisors to maximize asset valueTradingView·Oct 7, 2026 at 01:33 PMCVKD-3.93%
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor ConferenceGlobeNewswire·Sep 21, 2026 at 08:30 PMCVKD-3.93%
Vital Farms Targets $800M Revenue as Niche Equities Show Q2 Operational DivergenceGlobal Report·Sep 15, 2026 at 10:12 AMCVKD-3.93%HCC-0.10%
Weekly Recap | CVKD.US -20.78%, most brokers rate it buyWeekly Review·Sep 5, 2026 at 06:35 AMCVKD-3.93%
Cadrenal Therapeutics CEO presents at H.C. Wainwright Global Investment ConferencePUBT·Sep 3, 2026 at 12:04 PMCVKD-3.93%
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga_article·Sep 1, 2026 at 12:06 PMLABT+3.00%CLGN-3.60%
Regulatory Clarity and De-Risked Phase 3 Plan Support Cadrenal Buy Rating, $13 Target UnchangedTip Ranks·Sep 1, 2026 at 10:25 AMCVKD-3.93%
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga_article·Aug 31, 2026 at 05:06 PMAEMD+2.56%AIM-1.88%
Cadrenal Maintained at Buy as Partnership-Focused Strategy Supports Unchanged $13 Price TargetTip Ranks·Aug 14, 2026 at 10:26 AMCVKD-3.93%
Cadrenal Therapeutics Q2 net loss narrows 9.39% to $3.3 millionPUBT·Aug 13, 2026 at 08:24 PMCVKD-3.93%
